Compare RDIB & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDIB | PROF |
|---|---|---|
| Founded | 1937 | N/A |
| Country | United States | Canada |
| Employees | 2025 | N/A |
| Industry | Movies/Entertainment | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 244.6M |
| IPO Year | N/A | 2017 |
| Metric | RDIB | PROF |
|---|---|---|
| Price | $8.51 | $6.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 1.9K | ★ 53.6K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | $16.25 | $92.40 |
| Revenue Next Year | $4.04 | $64.10 |
| P/E Ratio | ★ N/A | $33.53 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $8.10 | $3.92 |
| 52 Week High | $17.40 | $8.95 |
| Indicator | RDIB | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 45.64 |
| Support Level | N/A | $6.47 |
| Resistance Level | $12.53 | $7.06 |
| Average True Range (ATR) | 0.48 | 0.31 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 17.90 | 30.88 |
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.